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Abstract 
Hypercholesteromia is one of the main risk factors of cardiovascular disease, causing 
high blood pressure and atherosclerosis. This has necessitated development of methods 
or substances which would reduce cholesterol uptake from the digestive tract or destroy 
cholesterol by enzymatic reactions. One of the practical approaches to protect the human 
body from high cholesterol levels is to inhibit the cholesterol-synthesizing ability of the 
organism. Lovastatin is a metabolite of mold fungi from the different genera. However, its 
presence has also been detected in fruiting bodies and submerged cultivated mycelia of 
some species of Higher Basidiomycetous fungus, especially in the species of genus Pleu-
rotus – P. ostreatus and P. eryngii. We are screening Higher Basidiomycetous mush-
rooms for identification of commercially recoverable quantities of lovastatin.  Since lovas-
tatin quantification in a large number of fungal samples is required, a simple, rapid and 
accurate analytical method was required. Use of HPTLC for quantitative measurements 
of lovastatin in fungal biomass has not yet been reported. In the present study a simple, 
precise, specific and accurate TLC Densitometric method for estimation of lovastatin in 
Higher Basidiomycetous mushrooms was developed, validated and used for estimation of 
lovastatin content in the cultured mycelia of Pleurotus spp. The develop method was vali-
dated for linearity, accuracy, precision, LOD, LOQ, spiking, robustness as per the ICH 
guidelines. The Rf and % recovery value for Lovastatin 0.52 and 99.15 respectively. De-
veloped analytical methods showed good separation and recovery of Lovastatin.  
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INTRODUCTION 
Lovastatin (monacolin K, Mevinolin; Mev) is one 
of the most interesting fungal secondary metabo-
lites. Lovastatin and related compounds contain a 
naphthalene ring system, a 13-hydroxylactone 
and methylbutyric acid. Lovastatin inactive in lac-
tone form is hydrolyzed to the biologically active 
form i.e. β-hydroxy acid in the body (Moore et al. 
1985) (Fig. 1). These fungal metabolites are com-
petitive inhibitors of 3-hydroxy-3-methylgiutaryl-
CoA reductase (EC 1.1.1.34). This enzyme cata-
lyzes the rate-limiting step in the biosynthesis of 
cholesterol, the reduction of HMG-CoA to mevalo-
nate (Endo A. 1979; Endo et al. 1985; Goldstein 
and Brown, 1990; Gunde-cimerman et al. 1993). 
Thus, Lovastatin and also its analogues are po-
tent hypocholesterolemic and hypolipemic agents 
and effective substance for treatment of athero-
sclerosis and coronary heart disease (Endo A. 
1988; Frishman et al. 1989; Gunde-cimerman et 
al. 1995). Several fungal genera including Asper-
gillus, Penicillium, Monascus, Paecilomyces, 
Trichoderma, Scopulariopsis, Doratomyces and 
Pleurotus were able to synthesize Mevinolin (Endo 
A et al., 1976; Endo A. 1979; Alberts et al. 1985; 
Kumagai et al. 1990; Gunde-cimerman et al. 
1993).  
Various High performance liquid chromatography 
(HPLC) methods available for development and 
validation for the analysis of Lovastatin. HPLC is a 
versatile separation technique and is official in 
most of the pharmacopeias for determining con-
tent uniformity, purity profile, assay values and 
dissolution rates in unlimited number of mono-
graphs. The exact reason for this is availability of 
HPLC system in almost every laboratory. Howev-
er, it cannot be denied that more than often, the 
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 systems are working beyond their capacities and 
mostly dedicated. Who would like to change a well
-running stabilized column and prepare fresh solu-
tions only because few assorted samples even 
through urgent are required to be analyzed. Ana-
lyst usually has the tendency to wait until large 
number of similar samples is accumulated, even 
risking the product development work because of 
non-availability of analytical results. Is not the 
HPTLC, the answer in such situations-YES? It can 
simultaneously handle several samples even of 
divergent nature and composition supporting sev-
eral analysts at a given time. HPTLC is the most 
simple separation techniques today available to 
the analyst. It can be considered a time machine 
that can speed your work and allows you to do 
many things at a time usually not possible with 
other analytical techniques. HPTLC is now truly a 
modern contemporary of HPLC and GC and con-
tinues to be an active and versatile technique in 
research with large number of publications ap-
pearing each year. 
In the present investigation, an attempt was made 
to develop a simple and economical validated 
HPTLC with greater precision, accuracy and sen-
sitivity for the simultaneous estimation of Lovas-
tatin in pure and extraction forms.  
MATERIALS AND METHODS  
Chemicals and reagents: An analytically pure 
sample of Lovastatin obtained from Hi-media. 
Preparation of solutions 
Preparation of standard stock solution: The 
standard Lovastatin 10mg was weighed accurate-
ly and transferred to volumetric flask 10 ml. It was 
dissolved in the 10 ml methanol with the use of 
sonicator to obtain the final concentration of 1mg/
ml and the resulting solution was used as working 
stock solution. 
Preparation of sample solution: For the estima-
tion of Lovastatin, 1 ml of prepared standard stock 
solution dissolved with 9 ml Methanol and we ob-
tained the final concentration of 100ng/µl for work-
ing standard sample solution.  
Chromatography: Analysis was performed on 10 
cm × 10 cm HPTLC silica gel 60 F254 plates 
(Merck, Darmstadt, Germany) with concentrating 
zone .The TLC plates were saturated with metha-
nol. Activation was done in an oven at 50⁰C for 5 
min .Sample and standard zones were applied to 
the layer as bands by means of a CAMAG 
(Muttenz Switzerland) Linomat V automated spray
-on application equipped with a 100µL syringe 
(Hamilton, Reno, Nevada, USA).The slit dimen-
sion 6 mm × 0.45 mm and scanning speed of 20 
mm/sec was employed . Ascending development 
of the plates, migration distance 60mm , was per-
formed at 25 ± 2⁰C with Chloroform:Methanol 
(95:5, v/v), as mobile phase in a CAMAG twin 
trough chamber previously saturated for 20 min. 
The average development time was 30 min. After 
development the plates was dried at 50⁰C in an 
oven for 5 min. Densitometric scanning at λ=238 
nm was then performed with a CAMAG TLC 
Scanner-3 equipped with winCAT 1.4.4 software, 
using a deuterium light source.  
Validation of the method: Validation should not 
be seen separately from the development of a 
method. It starts from a clearly defined analytical 
goal, method selection, optimization, and develop-
ment, which is called prevalidation considerations 
before arriving at the elaboration of a validation 
protocol and is the starting point of the actual vali-
dation. After performing all the experiments de-
scribed in the validation protocol, obtained data 
are evaluated and compared with the acceptance 
criteria. If all criteria are met, the method can be 
regarded as valid. In a less-formal approach, 
some validation data may be incorporated from 
experiments, which were conducted previously as 
part of the method development. 
The above approach is widely accepted for valida-
tion of qualitative HPTLC methods for identifica-
tion during routine use. It is possible that the vali-
dation method in different situations may require 
some changes in the standard validation protocol. 
Such changes may include restrictions with re-
spect to relative humidity, waiting times, precision, 
etc. The validation protocol is a key instrument for 
structuring, regulating and documenting the vali-
dation processes, depending on the quality man-
agement system.  
RESULTS AND DISCUSSION 
The present study was aimed at development of 
speedy and cost-effective HPTLC technique for 
determination of lovastatin as pure and extraction 
forms. Different combinations of solvent systems 
in different proportion were tried as mobile phase. 
However mobile phase consisting of Chloroform: 
Methanol in the ratio of 95:5(v/v) was found to be 
more suitable with Rf values of 0.52, with satura-
tion time of 20 minute based on maximum absorb-
ance for optimum sensitivity . The drug showed 
good linearity in the range of 100-900 ng per spot 
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Fig. 1: Different forms of lovastatin (A) Lovastatin 
with lactone form, (B) Lovastatin with hydroxy acid 
form. 
(A) (B) 
Table 1. Calibration parameters for lovastatin. 
Parameters Results 
Linearity Range 100-900ng/spot 
Correlation co-efficient 0.99904 
Slope 169.468 
Intercept 1.837 
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 with coefficient of correlation value 0.99904 for 
peak area. From the recovery studies, the accura-
cy results were within the range of 98.48-99.64% 
and were found to be highly accurate. Checked 
after deliberate alteration of the peaks of interest 
remained unaffected by small changes of the op-
erational parameters (%RSD < 2). 
The appropriate volume of standard Lovastatin 
stock solution was prepared and applied on the 
TLC plates in the range of 1-9 µL to give a series 
of spots covering the range from 100 to 900 ng/
spot with the help of microliter syringe and 
scanned densitometrically at 238 nm. The stand-
ard peak – area was calculated for each concen-
tration level and a graph was plotted of standard 
concentration level and a graph was plotted of 
standard concentration against the peak area. 
Calibration parameters are given in table: 1. 
The developed method was validated for specifici-
ty, repeatability and accuracy. The method is 
found to be specific for lovastatin since it resolved 
the peak of lovastatin  
(Rf value=0.52) in presence of other excipients in 
the standard formulations (Fig. 5). The specificity 
was also confirmed by overlaying the spectra of 
standard lovastatin on TLC scanner in UV range 
(Fig. 4). Linearity range for lovastatin was found to 
be in range of 100-900ng/spot (Table 1). The cor-
relation coefficient (r=0.999904) (Y= 
169.468+1.837*X) and other method validation 
parameters are given in table 3. Prior to the preci-
sion of the instruments was checked by repeated 
scanning of the same spot  (500ng, 700ng, 900ng 
per spot) of lovastatin for three times and the %CV 
was found to be 0.99. Repeatability of the method 
was checked by analyzing a standard solution of 
lovastatin (500ng/µl) after application on a TLC 
plate (n=6) and the % CV for peak area was found 
to be 0.71. Accuracy of the method was evaluated 
by carrying out a recovery study. A known concen-
tration of the standard lovastatin solution (500ng/
spot) was added to a pre-analyzed sample solution 
(500ng/spot), extracted and quantified as men-
tioned above. The percentage recovery was found 
to be 99.15 (Table 2).  
Conclusion 
An HPTLC method to analyze lovastatin in pure 
and extraction forms was optimized. The extraction 
procedure was optimized to stability of the com-
pounds during analysis. The method was validated 
according to ICH guidelines. The method was line-
ar in the range 100-900 ng/µl and had a recovery 
of 99.15%. Repeatability and accuracy were ac-
ceptable. This method can be used to control the 
quality of lovastatin based products and would 
allow drug companies to marketing their products 
containing lovastatin to use an accurate and relia-
ble method of analysis that meets ICH standards. 
Based on this method, drug manufacture compa-
nies could develop and validate a method for quali-
ty control on their commercial products.  
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Fig. 2.  Linearity vurve of lovastatin. Fig. 3. Precision experiments for lovastatin standard. 
Fig. 4. Overlay absorption spectra of Standard  
lovastatin. 
Fig. 5. TLC chromatogram of lovastatin from lovas-
tatin standard.        
Table 2. Estimation of standard Lovastatin from its 
formulations. 
Formu-
lations 
Labeled 
amount (ng) 
Amount 
found (ng) 
% of lovas-
tatin found 
a 500 9.915±0.105 99.15±1.05 
b 500 9.843±0.118 98.43±1.18 
c 500 9.893±0.145 98.93±1.45 
Table 3. Method validation parameters. 
Parameter Results 
Instrumental Precision (%CV) (n=9) 0.99 
Repeatability (% CV) (n=6) 0.71 
Specificity Specific 
Accuracy (%) 99.15±1.05 
Linearity Range(ng/µl) 100-900 
Correlation coefficient 0.999 
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